drug · small molecule
patient view →mavorixafor
Marketedupdated 2mo agoby $XFOR X4 Pharmaceuticals, Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 10 investigational indications.
targets
C-X-C chemokine receptor type 4
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that